Singapore, Mar 10, 2010: New Zealand's Cell implant company Living Cell Technologies announced that its subsidiary LCT Biomedical has received registration of the encapsulation device as a delivery system in Russia.

Registration allows for the production, sale and use of LCT's capsules in all delivery applications - including cell, drug and biologics.

Dr Paul Tan, Chief Executive Officer of LCT said, “The registration of LCT's encapsulation technology is an important step in the commercial development of the company's living cell products, particularly as the Russian standard is acceptable in Europe.

“In addition to LCT's two lead products – Diabecell for treatment of Type 1 diabetes and NTCell for the treatment of Parkinson's disease - there is already interest in Russia for the use of the capsules as a drug and biologic delivery system.”

Eight patients with insulin dependent diabetes have received between one and three implants of Diabecell with positive initial results in the clinical trial in Moscow. LCT Biomedical was formed in 2009 to facilitate the commercial development of Diabecell in Russia.